These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9261545)

  • 1. Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies.
    Antonelli G; Simeoni E; Currenti M; De Pisa F; Colizzi V; Pistello M; Dianzani F
    Biotherapy; 1997; 10(1):7-14. PubMed ID: 9261545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy.
    Antonelli G
    Antiviral Res; 1994 Jul; 24(2-3):235-44. PubMed ID: 7526794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B.
    Arends P; van der Eijk AA; Sonneveld MJ; Hansen BE; Janssen HL; Haagmans BL
    Antivir Ther; 2014; 19(4):423-7. PubMed ID: 24296674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biological basis for clinical use of interferon.
    Dianzani F; Antonelli G; Capobianchi MR
    J Hepatol; 1990; 11 Suppl 1():S5-10. PubMed ID: 1706739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the practical significance of antibodies to interferons?
    Dianzani F; Antonelli G
    BioDrugs; 1998 Mar; 9(3):187-95. PubMed ID: 18020559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
    Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
    Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo development of antibody to interferons: an update to 1996.
    Antonelli G
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S39-46. PubMed ID: 9241615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of treatment with interferon.
    Strander H
    Med Oncol Tumor Pharmacother; 1989; 6(1):87-91. PubMed ID: 2471026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferons as biomarkers and effectors: lessons learned from animal models.
    Berry CM; Hertzog PJ; Mangan NE
    Biomark Med; 2012 Apr; 6(2):159-76. PubMed ID: 22448790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The interferon system. A review of biological principles and clinical uses].
    Schneider FJ
    Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of interferon therapy].
    Dittrich C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
    Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
    Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-viral and anti-neoplastic actions of interferon--with special reference to its clinical application].
    Imanishi J
    Nihon Rinsho; 1980 Sep; 38(9):3272-81. PubMed ID: 6166771
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological basis for the clinical use of interferon.
    Dianzani F
    Gut; 1993; 34(2 Suppl):S74-6. PubMed ID: 7686123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA control of interferons and interferon induced anti-viral activity.
    Sedger LM
    Mol Immunol; 2013 Dec; 56(4):781-93. PubMed ID: 23962477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-alpha preparations.
    Antonelli G; Currenti M; Turriziani O; Riva E; Dianzani F
    J Infect Dis; 1992 Mar; 165(3):593-4. PubMed ID: 1371537
    [No Abstract]   [Full Text] [Related]  

  • 18. Current view on the perspectives of interferon therapy.
    Borecký L
    Acta Virol; 1986 Mar; 30(2):161-9. PubMed ID: 2425613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UCLA conference. Interferon: immunobiology and clinical significance.
    Stiehm ER; Kronenberg LH; Rosenblatt HM; Bryson Y; Merigan TC
    Ann Intern Med; 1982 Jan; 96(1):80-93. PubMed ID: 6172066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon, oligoadenylate synthetase and oligoadenine nucleotide--a cell biological triad].
    Bonnevie-Nielsen V
    Ugeskr Laeger; 1990 Apr; 152(16):1140-3. PubMed ID: 1691881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.